Literature DB >> 11815397

Polymorphism of the DNA repair gene XRCC1 and risk of primary lung cancer.

Jae Yong Park1, Su Yeon Lee, Hyo-Sung Jeon, Nack Chun Bae, Sang Chul Chae, Soyoung Joo, Chang Ho Kim, Jae-Ho Park, Sin Kam, In San Kim, Tae Hoon Jung.   

Abstract

DNA repair plays a critical role in protecting the genome of the cell from insults of cancer-causing agents, such as those found in tobacco smoke. Reduced DNA repair capacity, therefore, can increase the susceptibility to smoking-related cancers. Recently, three coding polymorphisms in X-ray cross-complementing group 1 (XRCC1) DNA repair gene have been identified, and it is possible that these polymorphisms may affect DNA repair capacity and thus modulate cancer susceptibility. We investigated the relationship between the codon 399 polymorphism in XRCC1 gene and lung cancer risk in male smokers. The study population consisted of 192 lung cancer patients and 135 healthy controls. The distribution of XRCC1 genotypes was not significantly different between cases and controls. When the cases were categorized by histological type, however, the presence of at least one Gln allele was associated with a significant increased risk for squamous cell carcinoma [crude odds ratio (OR) = 1.77, 95% confidence interval (CI) = 1.06-2.93 and adjusted OR = 1.66, 95% CI = 0.99-2.79]. The risk for the disease increased as the number of Gln alleles increased (Arg/Gln genotype: adjusted OR = 1.45, 95% CI = 0.84-2.5; Gln/Gln genotype: adjusted OR = 3.26, 95% CI = 1.17-9.15). When the subjects dichotomized by cigarette consumption into two pack-year groups (< or =40 pack-years, >40 pack-years), the Gln allele was associated with an increased risk for squamous cell carcinoma only in the group of individuals having < or =40 pack-years of smoking (Arg/Gln genotype: adjusted OR = 1.48, 95% CI = 0.78-2.8; Gln/Gln genotype: adjusted OR = 5.75, 95% CI = 1.46-22.69). These results suggest that XRCC1 codon 399 polymorphism may be an important genetic determinant of squamous cell carcinoma of the lung in persons with lower degrees of cigarette use.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11815397

Source DB:  PubMed          Journal:  Cancer Epidemiol Biomarkers Prev        ISSN: 1055-9965            Impact factor:   4.254


  39 in total

1.  XRCC1 gene polymorphisms and lung cancer susceptibility: a meta-analysis of 44 case-control studies.

Authors:  Liping Dai; Fujiao Duan; Peng Wang; Chunhua Song; Kaijuan Wang; Jianying Zhang
Journal:  Mol Biol Rep       Date:  2012-06-23       Impact factor: 2.316

2.  Note of clarification of data in the paper titled X-ray repair cross-complementing group 1 codon 399 polymorphism and lung cancer risk: an updated meta-analysis.

Authors:  Wenlong Zhai; Ruo Feng; Haiyu Wang; Yadong Wang
Journal:  Tumour Biol       Date:  2015-04-03

3.  Effect of ERCC1 polymorphisms and the modification by smoking on the survival of non-small cell lung cancer patients.

Authors:  So-Yeon Park; Yun-Chul Hong; Jin-Hee Kim; Seung-Min Kwak; Jae-Hwa Cho; Hong-Lyeol Lee; Jeong-Seon Ryu
Journal:  Med Oncol       Date:  2006       Impact factor: 3.064

4.  Correlations of MGMT genetic polymorphisms with temozolomide resistance and prognosis of patients with malignant gliomas: a population-based study in China.

Authors:  H-W Wang; Z-K Xu; Y Song; Y-G Liu
Journal:  Cancer Gene Ther       Date:  2017-04-14       Impact factor: 5.987

5.  Carcinogenesis-related changes in iron metabolism in chronic obstructive pulmonary disease subjects with lung cancer.

Authors:  Kamil Brzóska; Teresa Bartłomiejczyk; Barbara Sochanowicz; Magdalena Cymerman; Jacek Grudny; Jacek Kołakowski; Marcin Kruszewski; Paweł Śliwiński; Kazimierz Roszkowski-Śliż; Lucyna Kapka-Skrzypczak
Journal:  Oncol Lett       Date:  2018-09-19       Impact factor: 2.967

6.  Pharmacodynamic genes do not influence risk of neutropenia in cancer patients treated with moderately high-dose irinotecan.

Authors:  Janelle M Hoskins; Gary L Rosner; Mark J Ratain; Howard L McLeod; Federico Innocenti
Journal:  Pharmacogenomics       Date:  2009-07       Impact factor: 2.533

7.  Prognostic importance of DNA repair gene polymorphisms of XRCC1 Arg399Gln and XPD Lys751Gln in lung cancer patients from India.

Authors:  Leelakumari Sreeja; Volga S Syamala; Vani Syamala; Sreedharan Hariharan; Praveenkumar B Raveendran; R V Vijayalekshmi; Jayaprakash Madhavan; Ravindran Ankathil
Journal:  J Cancer Res Clin Oncol       Date:  2007-10-19       Impact factor: 4.553

8.  Network-based elucidation of human disease similarities reveals common functional modules enriched for pluripotent drug targets.

Authors:  Silpa Suthram; Joel T Dudley; Annie P Chiang; Rong Chen; Trevor J Hastie; Atul J Butte
Journal:  PLoS Comput Biol       Date:  2010-02-05       Impact factor: 4.475

9.  Lung cancer risk and genetic polymorphisms in DNA repair pathways: a meta-analysis.

Authors:  Chikako Kiyohara; Koichi Takayama; Yoichi Nakanishi
Journal:  J Nucleic Acids       Date:  2010-10-14

10.  Association between polymorphisms in DNA repair genes and survival of non-smoking female patients with lung adenocarcinoma.

Authors:  Zhihua Yin; Baosen Zhou; Qincheng He; Mingchuan Li; Peng Guan; Xuelian Li; Zeshi Cui; Xiaoxia Xue; Meng Su; Rui Ma; Weijun Bai; Shuyue Xia; Yanduo Jiang; Shun Xu; Yi Lv; Xun Li
Journal:  BMC Cancer       Date:  2009-12-15       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.